A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major

NCT06465550 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

β-thalassemia

Interventions

GENETIC: BD211

Sponsor

Shanghai BDgene Co., Ltd.